1093557 - Dexcom Inc - SEC Form 4 Insider Trading Screener

Manufactured Goods - Specialty Instruments - Surgical & Medical Instruments & Apparatus - DXCM (1093557)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
Real-time CSV, Options, Alerts
100 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
S24+0+2-3+0

X

Filing Date

Trade Date

Ticker

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

2017-11-20
DXCMSayer Kevin RPres, CEOS - Sale$55.00-12,000286,826-4%-$660,000
2017-11-20
DXCMKahn BarbaraDirS - Sale$54.58-3,00027,448-10%-$163,727
2017-11-07
DXCMAltman Steven RDirP - Purchase$50.01+25,00062,855+66%+$1,250,250
2017-11-06
DXCMAltman Steven RDirP - Purchase$49.61+10,00037,855+36%+$496,100
2017-10-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$44.82-1,63585,564-2%-$73,274
2017-09-25
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$69.77-1,63587,199-2%-$114,080
2017-09-25
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$69.81-1,45099,326-1%-$101,219
2017-09-20
DXCMSayer Kevin RPres, CEOS - Sale$69.34-6,000298,826-2%-$416,044
2017-09-11
DXCMSayer Kevin RPres, CEOD - Sale to issuer$71.81-15,854304,826-5%-$1,138,530
2017-09-11
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.D - Sale to issuer$71.81-7,311100,776-7%-$525,028
2017-09-11
DXCMMurphy Patrick MichaelVP, Legal Aff, Chf Compl OfcrD - Sale to issuer$71.81-1,32233,131-4%-$94,937
2017-09-11
DXCMMoy JeffreySVP, OperationsD - Sale to issuer$71.81-6,430115,810-5%-$461,760
2017-09-11
DXCMLeach Jacob StevenSVP, Research, DevelopmentD - Sale to issuer$71.81-6,342138,019-4%-$455,441
2017-09-11
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalD - Sale to issuer$71.81-7,53189,282-8%-$540,827
2017-09-11
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$72.27-3,24489,282-4%-$234,441
2017-09-11
DXCMDoubleday RichardEVP, Chief Commercial OfficerD - Sale to issuer$71.81-7,53188,834-8%-$540,827
2017-09-07
DXCMBlackford Quentin S.EVP, CFO, PFO, PAOA - Grant$0.00+62,35863,756>999%+$62
2017-08-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$75.26-3,987108,087-4%-$300,045
2017-08-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$75.26-1,63596,180-2%-$123,053
2017-08-23
DXCMAce Heather SSVP HRD - Sale to issuer$75.33-2,61746,766-5%-$197,145
2017-08-11
DXCMSayer Kevin RPres, CEOS - Sale$69.77-6,000320,680-2%-$418,637
2017-08-10
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$71.18-3,24499,989-3%-$230,921
2017-07-24
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$69.47-1,450112,074-1%-$100,725
2017-07-12
DXCMSayer Kevin RPres, CEOS - Sale$71.86-6,000326,680-2%-$431,174
2017-07-10
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$71.55-3,200103,233-3%-$228,972
2017-06-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$78.22-3,18797,815-3%-$249,273
2017-06-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$78.19-1,450113,524-1%-$113,378
2017-06-12
DXCMBalo Andrew KEVP, Clinical, RegulatoryS - Sale$69.06-3,200106,433-3%-$220,989
2017-06-12
DXCMSayer Kevin RPres, CEOS - Sale$69.07-6,000332,680-2%-$414,411
2017-06-01
DXCMSkyler Jay SDirA - Grant$0.00+4,55336,810+14%+$5
2017-06-01
DXCMKahn BarbaraDirA - Grant$0.00+4,35330,448+17%+$4
2017-06-01
DXCMAugustinos NicholasDirA - Grant$0.00+4,35331,015+16%+$4
2017-06-01
DXCMFoletta Mark GDirA - Grant$0.00+4,95220,595+32%+$5
2017-06-01
DXCMCollins Richard AlexanderDirA - Grant$0.00+5,3555,855>999%+$5
2017-06-01
DXCMAltman Steven RDirA - Grant$0.00+4,35327,855+19%+$4
2017-06-01
DXCMTopol EricDirA - Grant$0.00+4,653104,562+5%+$5
2017-06-01
DXCMAbbey DonaldEVP QualityD - Sale to issuer$66.38-7,78474,726-9%-$516,707
D
2017-05-24
DXCMGregg Terrance HExec COBM - OptEx$6.85+30,000536,902+6%+$205,500
2017-05-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$68.24-1,450114,974-1%-$98,949
2017-05-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$68.29-3,182101,002-3%-$217,290
D
2017-05-17
DXCMSayer Kevin RPres, CEOM - OptEx$8.79+3,649338,680+1%+$32,075
D
2017-05-17
DXCMSayer Kevin RPres, CEOS - Sale+OE$68.39-8,649338,680-2%-$591,525
2017-05-16
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.G - Gift$0.00-1,000116,424-1%-$0
2017-05-10
DXCMBalo Andrew KEVP, Clinical, RegulatoryS - Sale$71.93-3,200109,633-3%-$230,176
2017-04-24
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$75.89-1,450117,424-1%-$110,041+3+8
2017-04-24
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$75.78-3,182104,184-3%-$241,131+3+8
2017-04-20
DXCMGregg Terrance HExec COBS - Sale$74.10-15,000506,902-3%-$1,111,5000+4
D
2017-04-17
DXCMSayer Kevin RPres, CEOM - OptEx$8.79+10,000343,680+3%+$87,900+2+1
D
2017-04-17
DXCMSayer Kevin RPres, CEOS - Sale+OE$75.63-10,000343,680-3%-$756,317+2+1
2017-04-10
DXCMBalo Andrew KEVP, Clinical, RegulatoryS - Sale$78.19-3,200112,833-3%-$250,208-1-3-10
2017-03-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$76.25-3,987118,874-3%-$304,006+1+3-10
2017-03-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$76.38-3,182107,366-3%-$243,029+1+3-10
2017-03-22
DXCMRoper JessSVP, CFOS - Sale$75.97-2,00054,949-4%-$151,937+1+3-10
D
2017-03-17
DXCMSayer Kevin RPres, CEOM - OptEx$8.79+10,000343,680+3%+$87,900+1+9-3
D
2017-03-17
DXCMSayer Kevin RPres, CEOS - Sale+OE$77.82-10,000343,680-3%-$778,158+1+9-3
2017-03-14
DXCMKahn BarbaraDirS - Sale$77.36-3,00026,095-10%-$232,080+2-1-2
D
2017-03-10
DXCMLeach Jacob StevenSVP, Research, DevelopmentD - Sale to issuer$77.55-9,961144,255-6%-$772,4820-1-1
D
2017-03-10
DXCMLeach Jacob StevenSVP, Research, DevelopmentM - OptEx$7.63+7,500144,255+5%+$57,2250-1-1
DM
2017-03-09
DXCMLeach Jacob StevenSVP, Research, DevelopmentS - Sale+OE$77.63-21,317144,255-13%-$1,654,8880-1-1
2017-03-10
DXCMValdes Jorge ACTOD - Sale to issuer$77.55-16,91244,521-28%-$1,311,5360+30
2017-03-13
DXCMValdes Jorge ACTOS - Sale$77.74-14,40044,521-24%-$1,119,5140+30
2017-03-10
DXCMRoper JessSVP, CFOD - Sale to issuer$77.55-9,60656,949-14%-$744,9510+30
2017-03-10
DXCMMoy JeffreySVP, OperationsD - Sale to issuer$77.55-11,893122,150-9%-$922,3090+30
2017-03-10
DXCMBalo Andrew KEVP, Clinical, RegulatoryD - Sale to issuer$77.55-13,430116,033-10%-$1,041,5050+30
2017-03-10
DXCMBalo Andrew KEVP, Clinical, RegulatoryS - Sale$77.71-3,200116,033-3%-$248,6720+30
2017-03-08
DXCMDoubleday RichardEVP, Chief Commercial OfficerA - Grant$0.00+27,510110,548+33%+$28-1-1+1
2017-03-10
DXCMDoubleday RichardEVP, Chief Commercial OfficerD - Sale to issuer$77.55-13,429110,548-11%-$1,041,427-1-1+1
2017-03-08
DXCMMoy JeffreySVP, OperationsA - Grant$0.00+21,883134,043+20%+$22-1-1+1
2017-03-08
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.A - Grant$0.00+27,510122,861+29%+$28-1-1+1
2017-03-10
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.D - Sale to issuer$77.55-15,058122,861-11%-$1,167,757-1-1+1
D
2017-03-08
DXCMLister JohnGM, EMEAA - Grant$0.00+23,13484,034+38%+$23-1-1+1
D
2017-03-10
DXCMLister JohnGM, EMEAD - Sale to issuer$77.55-9,69884,034-10%-$752,086-1-1+1
D
2017-03-09
DXCMLister JohnGM, EMEAM - OptEx$8.85+3,00084,034+4%+$26,550-1-1+1
D
2017-03-09
DXCMLister JohnGM, EMEAS - Sale+OE$77.67-3,00084,034-3%-$233,002-1-1+1
2017-03-08
DXCMSayer Kevin RPres, CEOA - Grant$0.00+81,280343,680+31%+$81-1-1+1
M
2017-03-08
DXCMSayer Kevin RPres, CEOD - Sale to issuer$77.55-36,991343,680-10%-$2,868,674-1-1+1
2017-03-08
DXCMGregg Terrance HExec COBA - Grant$0.00+30,887521,902+6%+$31-1-1+1
2017-03-10
DXCMGregg Terrance HExec COBD - Sale to issuer$77.55-16,173521,902-3%-$1,254,226-1-1+1
2017-03-08
DXCMBalo Andrew KEVP, Clinical, RegulatoryA - Grant$0.00+28,761132,663+28%+$29-1-1+1
2017-03-08
DXCMAbbey DonaldEVP QualityA - Grant$0.00+27,51082,510+50%+$28-1-1+1
2017-03-08
DXCMMurphy Patrick MichaelVP, Legal Aff, Chf Compl OfcrA - Grant$0.00+11,36134,453+49%+$11-1-1+1
2017-03-10
DXCMMurphy Patrick MichaelVP, Legal Aff, Chf Compl OfcrD - Sale to issuer$77.55-6,03634,453-15%-$468,095-1-1+1
D
2017-03-06
DXCMSkyler Jay SDirM - OptEx$7.31+31,89032,257>999%+$233,116-1-1+2
D
2017-03-06
DXCMSkyler Jay SDirS - Sale+OE$78.13-31,89032,257-50%-$2,491,572-1-1+2
2017-02-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$78.42-3,18296,315-3%-$249,530+1+3+5
2017-02-22
DXCMRoper JessSVP, CFOS - Sale$78.76-2,33366,428-3%-$183,759+1+3+5
D
2017-02-17
DXCMSayer Kevin RPres, CEOM - OptEx$8.79+10,000299,391+3%+$87,900-1-1-2
D
2017-02-17
DXCMSayer Kevin RPres, CEOS - Sale+OE$81.62-10,000299,391-3%-$816,177-1-1-2
D
2017-02-10
DXCMBalo Andrew KEVP, Clinical, RegulatoryM - OptEx$9.80+727103,872+1%+$7,125+3-1-5
D
2017-02-10
DXCMBalo Andrew KEVP, Clinical, RegulatoryS - Sale+OE$79.30-3,200103,872-3%-$253,760+3-1-5
D
2017-02-09
DXCMLister JohnGM, EMEAM - OptEx$8.85+3,00070,598+4%+$26,550+1+2-3
D
2017-02-09
DXCMLister JohnGM, EMEAS - Sale+OE$79.73-3,00070,598-4%-$239,204+1+2-3
D
2017-02-09
DXCMValdes Jorge ACTOM - OptEx$9.80+7,00075,833+10%+$68,600+1+2-3
D
2017-02-09
DXCMValdes Jorge ACTOS - Sale+OE$79.76-7,00075,833-8%-$558,316+1+2-3
2017-02-09
DXCMGregg Terrance HExec COBD - Sale to issuer$79.35-1,421507,1880%-$112,756+1+2-3
D
2017-02-01
DXCMValdes Jorge ACTOM - OptEx$9.80+13,90075,833+22%+$136,220-2-3-4
D
2017-02-01
DXCMValdes Jorge ACTOS - Sale+OE$80.00-13,90075,833-15%-$1,112,000-2-3-4
2017-01-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$79.50-3,18299,497-3%-$252,978-2-2-4
D
2017-01-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.M - OptEx$7.79+9,637110,409+10%+$75,072-2-2-4
D
2017-01-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale+OE$79.99-9,637110,409-8%-$770,908-2-2-4

Real-time CSV? Options? Alerts? Contact us!
AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top